Loading cancer entity…
Loading cancer entity…
Clinical trials
28 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (9)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04021069 | Using Clinicopathomic Markers to Predict Neoadjuvant Chemotherapy Response in Breast Cancer | unknown | — | 800 | Sunnybrook Health Sciences CentreOTHER | 1 | Jul 16, 2019 | clinicaltrials |
| NCT01038258 | Monitoring Response After The First Chemotherapy Cycle After Neoadjuvant Breast Cancer Therapy(PETBreast) | unknown | N/A | 80 | Auxilio Mutuo Cancer CenterOTHER | 1 | Jul 13, 2012 |
| clinicaltrials |
| NCT01126138 | Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC) | unknown | Phase 3 | 200 | Chinese Academy of Medical SciencesOTHER | 1 | May 4, 2011 | clinicaltrials |
Data updated 23 days agoSource updated Jul 16, 2019source: clinicaltrials